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Albuminuria: Marker or target in indigenous populations.
Background. Australian Aborigines in remote areas are
experiencing an epidemic of renal disease, type 2 diabetes,
hypertension, and cardiovascular disease. Adult deaths are in-
creased 3- to 6-fold, and renal failure more than 20-fold. Renal
disease is marked by albuminuria. We describe its distributions
and correlations in two remote communities in the Northern
Territory.
Methods. Observations in Community 1 included a screen of
939 adult participants (18+ years, 90% recruitment), a treat-
ment program, and 8 to 11 years of follow-up. In Community
2, a screen of 259 people, or 60% of adults, included HbA1c,
homocysteine, C-reactive protein (CRP), CMV serology, and
carotid intimal media thickness (CIMT). Albumin/creatinine
ratio (ACR) was measured by immunoassay in g/mol on ran-
dom urine, with microalbuminuria defined as 3.4 to 33, and overt
albuminuria as ACR 34+.
Results. Dipstick urine protein trace + correctly classified
76% of people with ACR 3.4+, and dipstick protein 1+ cor-
rectly classified 82% of people with ACR 34+. ACR was sta-
ble to glucose loading and water diuresis in subsets of people
in Community 1. ACR levels rose steeply with age. Rates of
micro- and overt albuminuria in Community 1 were 28% and
21%, and in Community B were 31% and 13%. ACR correlated
inversely with estimated glomerular filtration rate (GFR). ACR
also correlated directly with weight, blood pressure, cholesterol,
triglycerides, random glucose, HbA1c, homocysteine, and GGT
levels, and inversely with HDL cholesterol. ACR correlated
with skin sores, scabies, high titer antibodies to Helicobacter
pylori, high-titer CMV antibodies, with CRP over a greatly ele-
vated range and, inversely, with birth weight. Finally, ACR cor-
related with CIMT. Baseline ACR predicted loss of GFR over
time. ACR 3.4+ predicted all-cause and cardiovascular hospi-
talization, while ACR 34+ predicted all renal failure developing
over 11 years and all-cause natural deaths and cardiovascular
disease deaths. ACEi treatment for people with ACR 34+ re-
duced renal failure and natural deaths, but the hierarchical ef-
fect of higher ACRs within that group for renal and nonrenal
deaths was maintained.
Conclusion. Random urine ACR is a stable and robust
marker of renal disease, which is multideterminant. A broad
base of shared risk factors probably explains the simultaneous
emergence of the excessive renal and nonrenal chronic disease
morbidities from which these populations suffer. Thus, albumin-
uria is a unifying marker for the harmful effects of the spectrum
of chronic disease, and perhaps beyond. Dipstick urine protein
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is a useful surrogate for ACR when resources are constrained
and disease burdens high.
An epidemic of type 2 diabetes, hypertension, re-
nal, and cardiovascular disease has developed among
Australian Aborigines in the last 25 years. Incidence
rates of people entering treatment programs for end-
stage renal disease (ESRD) in remote areas are now
20 to more than 60 times those of non-Aboriginal Aus-
tralians in some regions [1, 2]. In adults, age standard-
ized rates of death, of which cardiovascular disease is the
leading cause, are 3 to >6 times those of non-Aboriginal
Australians [3]. These conditions are probably all part of
a single syndrome—a view supported by the chronology
of their development in individuals, their shared risk fac-
tors and associations, coexistence of their markers and
complications, and their shared susceptibility to certain
interventions for prevention and treatment. We propose
that albuminuria and proteinuria are powerfully reliable
markers of this syndrome, predictors of its complications,
and indicators of its response to treatment.
METHODS
Our observations are derived from studies on two re-
mote Aboriginal communities of different tribal groups,
in regions 700 km apart. The urine albumin/creatinine
ratio (ACR) on a random urine specimen was used as
the primary renal disease marker, using the Beckmann
immunoassay for albumin. Dipstick testing was also per-
formed on the same urines. In the first community, a cross-
sectional survey was done on 1495 people, or >90% of
those age 5+ years. In that community, ACR was also
measured in 166 adults in the fasting state, and again,
2 hours after a 75 g oral glucose challenge, and in 115
adolescents and young adults before and after a 2 g/kg
protein load under water diuresis. The associations of
ACR with a variety of simply measured parameters were
evaluated [4]. Disease progression, hospitalizations, renal
failure, and nonrenal deaths were then followed over a
period of up to 9.8 years (mean 5.8 years) [5, 6, 7]. Finally,
a treatment program was introduced for people with
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Fig. 1. Increasing albumin/creatinine ratio (ACR) with age in adults
(18+ years).
albuminuria and/or hypertension. It was conducted fairly
systematically for 3.5 years, and, after transfer to a
community agency, progressively neglected when health
services funds ran low [8, 9, 10]. In the second commu-
nity, 258 people, or 58% of all adults, participated in
a cross-sectional survey that included assays of “more
modern” cardiovascular and renal risk markers and ad-
ditional markers of infection; carotid intima-media thick-
ness (CIMT) was also measured as a structural marker of
cardiovascular risk [7, 11, 12].
RESULTS
Population distribution of ACR
Average levels of ACR increased inexorably with in-
creasing age, as shown for Community 1 in Figure 1.
The median populations levels are remarkable, given
that “normal” ACR levels are generally considered
<1.1 g/mol. Overall, 28% of adults had microalbumin-
uria, and 21% had overt albuminuria [4]. ACRs also rose
with age in adults in Community 2, with 31% overall hav-
ing microalbuminuria, and 13% having overt albuminuria
[7, 11].
Technical issues
Table 1 shows the correlations between urine dipstick
protein readings and ACR levels. Dipstick trace+ de-
tected 72.5% of people with ACR 3.4+ (microalbumin-
uria threshold), and correctly classified 76%. Dipstick
protein 1+ detected 85.6% of people with overt albu-
minuria (ACR 34+), and correctly classified 82%.
Urine ACR was very stable to the glucose challenge
and to protein and water loading, as shown in Figure 2.
There were strong consistencies of categorization across
Table 1. Correlations of urine dipstick test for protein with
simultaneous ACR in adults, N = 879
Correctly
Sensitivity Specificity classified
Dipstick protein trace+ 72.5% 79.7% 76.2%
for ACR 3.4+
Dipstick protein trace+ 90.9% 66.8% 71.9%
for ACR 34+
Dipstick protein 1+ 85.6% 81.4% 82.3%
for ACR 34+
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Fig. 2. Stability of urine ACR.
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Fig. 3. Reciprocal serum creatinine and ACR in adults.
the three ACR groupings—the agreement across 3 cat-
egories with glucose loading was 86%, kappa 0.79, and
with water and protein loading was 99%, kappa 0.78,
P < 0.0001 for both. The dichotomous thresholds of ACR
3.4+ and of 34+ were classified even more consistently.
Relationship of ACR to excretory renal function
Figure 3 shows the relationship in adults between the
inverse of the serum creatinine (10,000 × mmol/L) and
ACR, with adjustment for age and sex (R2 = 0.443). There
was an apparent increase in this surrogate estimate of
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Table 2. Factors correlating with ACR by category, adjusted for age and sex, in adults (18+ years)
N ACR <3.4 ACR 3.4–33 ACR 34+ P value
Hematuria ≥small by dipstick 876 7.1 (5.1–9.9) 15.9 (10.9–20.1) 22.6 (16.8–29.8) <0.0001
Weight kg 939 61.3 (59.9–62.6) 67.9 (66.1–69.7) 71.9 (70–74.1) <0.0001
BMI kg/m2 923 22.2 (21.7–22.7) 24.5 (23.9–25.2) 25.9 (25.2–26.7) <0.0001
Waist cm 877 84.6 (83–86) 90.8 (89–92) 95.0 (93–97) <0.0001
Hips cm 876 89.9 (89–91) 94.8 (93–96) 97.6 (96–99) <0.0001
Waist/hip ratio 871 0.943 (0.94–0.95) 0.959 (0.95–0.97) 0.975 (0.97–0.99) <0.0001
SBP mm Hg 915 117.5 (116–119) 122.6 (121–125) 128.7 (126–131) <0.0001
DBP mm Hg 915 70.6 (69–72) 75.1 (74–77) 80.9 (79–83) <0.0001
Cholesterol mmol/L 747 4.5 (4.3–4.6) 4.7 (4.5–4.8) 5.2 (5.0–5.4) <0.0001
Triglycerides mmol/L, gmean 745 1.57 (1.5–1.7) 1.87 (1.7–2.0) 2.43 (2.2–2.7) <0.0001
Fasting insulin U/L, gmean 389 7.2 (6.5–7.8) 9.9 (8.8–11.2) 10.2 (8.7–11.7) <0.0001
2-hr insulin U/L, gmean 338 29.5 (25.7–33.7) 40.7 (34.7–49) 38 (29.5–47.9) 0.0083
Fasting glucose mmol/L, gmean 440 4.68 (4.5–4.9) 5.89 (4.8–5.3) 5.69 (4.9–6.0) <0.0001
HbA1c %, median (25,75%)a 216 5.54 [5.26–6.15] 5.93 [5.52–7.44] 6.30 [5.83–9.76] 0.02
Diabetes % 939 5.1 (3.4–7.6) 10.2 (7.1–14.4) 23.5 (17.8–30.4) <0.0001
CV risk score, range 0–4 688 0.98 (0.9–1.1) 1.34 (1.2–1.5) 1.87 (1.7–2.0) <0.0001
CIMT, top quartile (=0.72 mm)a 204 9.1 [4.2–18.3] 19.1 [10.1–33.1] 19.2 [7.3–41.9] 0.2
GGT IU 745 40.0 (35–45) 53.2 (47–59) 61.3 (54–68) <0.0001
Scabies% 763 8.4 (6.0–11.7) 13.7 (9.7–19.1) 18.9 (13.3–26.2) 0.0055
H. pylori antibody titer 300+ % 477 27.3 921.9–33.5) 35.2 (27.3–44.0) 44.0 (34.6–53.5) 0.0153
CMV antibody, top quartile %a 195 10.8 (5.8–20) 28 (23.7–48.1) 31.0 [15.7–51.9] 0.001
CRP mg/L, g.meana 215 6.0 [5.2–6.9] 9.3 [7.6–11.2] 9.9 [7.3–13.4] <0.001
Fibrinogen g/L, g.meana 206 3.27 [3.03–3.23] 3.42 [3.22–3.64] 3.78 [3.42–4.12] 0.006
Total serum IgG g/L, g.meana 214 18.1 [17.3–19.0] 20.3 [19.0–21.6] 22.2 [20.1–24.6] <0.001
Serum albumin g/La 216 45.3 [44.8–45.7] 44.7 [44.1–45.3] 42.6 [41.6–43.6] <0.001
Hemoglobin g/La 216 140 [138–142] 137 [134–140] 134 [129–138] 0.07
Birth weight kgb 324 2.741 (2.67–2.81) 2.657 (2.54–2.68) 2.576 (2.41–2.75) 0.1889b
Birth weight <2.5 kg %c 324 28.9 (22.9–35.8) 37.9 (27.2–49.9) 49.6 (32.9–66.4) 0.0703
aData from Community 2.
bBirth weight available only in people up to the age of 38 years. Values adjusted for age, sex, and current weights. Trends by ACR category significant for females,
P < 0.0028, but not for males, P = 0.86.
cLBW, Values adjusted for age, sex, and current weight. Difference by ACR category significant for females, P = 0.0028, but not for males, P = 0.91.
GFR at subtle levels of increasing ACR, which was sig-
nificant (P < 0.001), as well as a clear inverse relationship
between GFR and ACR starting in the early overt albu-
minuria range (P < 0.0001). Models of GFR by Cockroft-
Gault and by the modified MDRD formula showed
similar curves, but with much less explanation of vari-
ance (R2 = 0.03 and R2 = 0.07, respectively). The mean
(95% CI) estimated GFRs by MDRD were 90.5 (87–92)
for those with ACR <3.4, 92.4 (82–96) for ACR 3.4–33,
80 (74–87) for ACR 34 to 99, and 62 (53–72) for ACR
≥100 g/mol.
Factors correlating with ACR
Table 2 shows the relationship of a wide range of
factors with increasing ACR, expressed in categories.
There was a significant relationship with microscopic
hematuria. Other correlations include all parameters of
increasing body weight or fat, with waist having the
strongest relationship. There was no correlation with
height (P = 0.83). They include many features of the
metabolic/hemodynamic syndrome X, including, hyper-
tension and diabetes, resulting in a correlation of ACR
with a cardiovascular risk factor score compiled from
measures of high BMI, hypertension, high cholesterol,
and low HDL levels. This association began at levels of
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Fig. 4. Composite cardiovascular risk factor score and baseline ACR
in adults in Community 1.
ACR well within the normal range, as shown in Figure 4.
The relationship of ACR to cardiovascular risk was also
supported by its correlation with CIMT in Community 2,
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Fig. 5. Carotid intima-media thickness in adults in Community 2, ad-
justed for age and sex.
shown in Figure 5, with the relationship beginning well
below the microalbuminuria threshold.
Higher ACRs were also marked by a high GGT, mark-
ers of infection, and inflammation, and inversely with
hemoglobin levels (marginally significant), with serum al-
bumin, and with birth weight. The inverse associations of
birth weight with albuminuria, and also with blood pres-
sure, which have been described in detail elsewhere [4,
13–15], operated over a continuum of birth weights. They
are mediated, in part at least, through birth weight’s in-
fluence on nephron number and kidney volume [16–18],
However, with birth weights available only in people up
to age 38 years, the effects in the community study are
only significant in females to this point.
While the relationship with hematuria probably marks
the inciting disease process, and/or ongoing renal dam-
age, many of the other factors are probably either risk
factors for renal disease or markers of the environment
in which renal disease arises. We have thus proposed a
multideterminant model of renal disease, in which the
simultaneous operation of more than one risk factor suc-
cessively amplifies the increase in ACR and loss of ex-
cretory renal function that accompanies increasing age.
In such a model, discussed in more detail elsewhere, and
subsequently supported by hypotheses by others [19], the
probability of overt albuminuria by middle age in people
with no risk factors is minimal, but is very high in people
with several risk factors [4].
Many people had concurrent or overlapping morbidi-
ties, a situation which increased with increasing age, as
shown for Community 1 in Figure 6. The figure also shows
that pathologic albuminuria is an early marker of prob-
lems, rather than the consequence of either hypertension
(≥140/90) or diabetes (WHO definition), at least by these
(probably insensitive) diagnostic criteria [20].
Ages 18-29 years,
N  = 450
All screened
ACR ≥3.4
Hypertension
Diabetes
Ages 30-44 years,
N  = 320  Ages 45+ years,N  = 169  
Fig. 6. Overlapping and coexisting morbidities, by age group.
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Fig. 7. Annual loss of GFR, mL/min, by baseline ACR category.
ACR predicts progression, morbidity, and death
Baseline ACR strongly predicted the rates of loss renal
function over time, as shown in Figure 7, and described
in more detail elsewhere [5].
As shown in Figure 8, baseline ACR also predicted
hospitalizations in people in Community 1, including, but
not restricted to, those related to cardiovascular causes
[7]. People with microalbuminuria had a 40% (95% CI
1–80, P = 0.03) higher rate of admission unrelated to
hemodialysis or pregnancy than those with lower ACRs,
after adjustment for age and sex, and those with ACR
34+ had an 100% increase (95% CI 50–170, P < 0.001).
For cardiovascular admissions, there was a 20% increase
in people with microalbuminuria that was not significant,
but the 90% increase (95% CI 10–220) in those with ACR
34+ was significant (P < 0.001).
Overt albuminuria at baseline predicted all 16 cases
of renal failure in the pretreatment program era. How-
ever, as shown in Figure 9, pathologic ACR also predicted
nonrenal deaths, including cardiovascular deaths, over a
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Fig. 8. Hospitalizations in adults, by baseline ACR category, adjusted
for age and sex.
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Fig. 9. Rates (95% CI) of terminal events per 1000 person-years by
baseline ACR category.
continuum. Figure 10 shows the hazard ratios (HR) for
all-cause mortality by baseline ACR category.
Urine protein by dipstick also predicted deaths, shown
in Figure 11, although with less discrimination among cat-
egories. The adjusted HR (95% CI) for all-cause natural
deaths in people with urine protein 1+ or 2+ was 2.2
(1.1–4.3), P = 0.028, and for those with baseline protein
of 3+ or 4+, was 4.1 (2.3–7.5), P < 0.0001.
Treatment effects
A systematic treatment program with angiotensin-
converting enzyme inhibitor for people with pathologic
albuminuria or hypertension resulted in a dramatic fall
in blood pressure and stabilization of renal function on
a group basis, despite an estimate that only two thirds
of people were taking their medicine with any regularity.
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Fig. 10. All-cause mortality by baseline ACR, hazard ratio (95% CI),
adjusted for age and sex.
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Over a mean treatment period of 3.4 years, renal deaths
fell by two thirds, and nonrenal deaths by 50% in peo-
ple with ACR 34+ at baseline, with benefit at every level
of overt ACR [8, 9]. Substantial cost savings were es-
timated in dialysis averted or delayed alone [9, 21]. In
its fourth year, this program was handed over to the lo-
cal health board, and the program’s intensity diminished
when health services funding later fell short—blood pres-
sures and ACR levels rose and estimated GFR fell, and
the community profile as a whole showed a rebound in
terminal events, shown in Figure 12 [10].
DISCUSSION
The random urine ACR has high accuracy and repro-
ducibility. It is an excellent test for epidemiologic study of
renal and related chronic disease. Assays for total, rather
than just immunoreactive albumin, which expose more
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“pathologic” albuminuria in the lower ranges, might fur-
ther improve discrimination [22].
The ACR is a powerful marker of renal disease and
its severity and predicts renal failure. It also marks,
more broadly, risk for premature nonrenal morbidity and
deaths, which include, but are not restricted to, those of
cardiovascular origin. It appears that all the excess renal
failure in this population would be avoided if ACR levels
were comparable to non-Aboriginal Australians. It is less
widely appreciated that the great majority of excess non-
renal deaths would also be avoided. Thus, a simple test
on random urine marks the overall “force of mortality”
in this group.
The multideterminant model of renal disease should
distract us from pursuit of single-model causes, to con-
sider the problem in context of the broader environ-
ment. In our study population, the environment has a
wide range of risk factors of high density, a feature of so-
cioeconomic disadvantage and rapid societal and health
transition. The ultimate solutions for primary prevention
are socioeconomic, rather than medical.
The cross-sectional relationships of albuminuria to
blood pressure, measures of glycemia, and cardiovascular
risk are compatible with the association of renal disease
with hypertension, diabetes, and cardiovascular disease.
However, these relationships operate at levels of these
variables well before they warrant clinical “diagnoses.”
These conditions are probably all part of a single syn-
drome, rather than separate entities. Pathologic albumin-
uria appears to be one of the earliest and most prevalent
elements of the syndrome [21], rather than a later devel-
opment or complication. This has obvious implications
for screening and for prevention.
The relationships of ACR to markers of infection, in-
flammation, and low birth weight that our studies have ex-
posed are relatively novel and very important. The links
to infectious markers do not necessarily imply specific
individual nephropathic effects, although this is clearly
documented for PSGN [23], but probably flag the effect
of the “burden of disease” on the kidneys and vasculature
more generally. Thus, interventions to reduce infections
and improve birth weights should ultimately be rewarded
by reduced chronic disease and renal deaths, as well as
more direct outcomes of reduced infant deaths and infec-
tious deaths. The expanded menu of shared risk factors
helps to explain the simultaneous emergence of renal and
cardiovascular disease in the chronic disease epidemic in
these indigenous people.
If albuminuria marks systemic vascular compromise, it
might flag generalized microvascular leakage of albumin
[24, 25], which is reclaimed into the vascular compartment
in nonrenal tissues, but insufficiently reclaimed in the re-
nal tubules: our multideterminant model suggests that
the scope of factors inducing such vascular compromise
is broad, and not limited to metabolic and hemodynamic
factors.
The nature of the relationship between ACR and GFR
requires more investigation. We do not know the ex-
tent to which albuminuria might be initiated by com-
pensatory hypertrophy of existing nephrons in people
with marginal renal functioning mass in relation to body
size and metabolic demands, as well as propagated by
this process as renal mass is subsequently lost. We do
not know the potential for people with lower estimated
GFRs without significant albuminuria to progress to re-
nal insufficiency. Nor do we know whether renal function
can be indefinitely spared if factors like blood pressure
and metabolic status are successfully modified but sub-
stantial albuminuria persists. A 15-year follow-up study
in Community 1, now underway, might help answer some
of these questions.
While the urine ACR is useful for screening, diagnosis,
and treatment, there are good alternatives in places with
limited resources. In this study, the urine protein dipstick
test was a good substitute for detecting renal disease. This
was probably facilitated by the generally concentrated
urines due to the ambient heat, but this circumstance also
applies in many other minority and indigenous settings.
Testing with sulfosalicylic acid, at fractions of a cent, is
another good option. A compromise approach is to se-
lect people with positive results on these cruder tests, and
those who are diabetic or hypertensive, for an ACR. We
use this approach in the Australian Aboriginal Chronic
Disease Outreach Program [26, 27], being driven by
expedience, distance from laboratory facilities, and the
fact that Australia’s Medicare reimburses costs for ACR
tests for diabetics or people with a suspicion of disease,
but not for “well-person” screening.
Therapeutic policies, agents, and monitoring mecha-
nisms for treatment will also depend heavily on local
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resources. Where the burden of renal disease is great and
much goes unattended, the management of people with
subtle levels of proteinuria without attendant morbidity
is not a high priority. Where available, use of ACEi or
ARB therapies is probably best for people with renal
disease, but much is gained by lowering blood pressure,
regardless of agent. Use of combination therapy, super-
dose ACEi treatment, or joint ACEi/ARB therapy can be
guided by blood pressure targets of <125/75 mm Hg [28]
until we know that specific downward titration of urine
ACR brings distinct added benefit.
Reprint requests to Dr. Wendy Hoy, Professor of Medicine, Director,
Centre for Chronic Disease, The University of Queensland, Royal Bris-
bane Hospital, Level F, Block 6, Herston, Queensland, 4029, Australia.
E-mail: wendy@kdrp.org
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